New research has revealed exciting news for people with type 2 diabetes and chronic kidney disease. A medication called sotagliflozin, which is part of a group of drugs known as SGLT2 inhibitors, may help protect both the heart and kidneys.
SGLT2 inhibitors are drugs that help lower blood sugar levels by causing the body to remove extra glucose through urine. But these medications do more than just control blood sugar—they also help with weight loss, lower blood pressure, and protect the heart and kidneys.
Type 2 diabetes is a long-term condition that affects how the body uses sugar for energy. If not managed well, it can cause serious problems such as kidney damage and heart disease. Many people with diabetes also develop chronic kidney disease, which makes their health even more complicated.
That’s where sotagliflozin may help. This medication blocks not just SGLT2, but also SGLT1—a similar protein that affects how sugar is absorbed in the body. This dual action makes it a unique and powerful option.
The recent research comes from a major clinical trial called the SCORED trial. This study looked at how well sotagliflozin worked in people who had both type 2 diabetes and chronic kidney disease, along with a higher risk of heart disease.
The trial was done in a careful way—double-blind and placebo-controlled—meaning that neither the participants nor the researchers knew who was getting the real drug or a placebo.
The results were very encouraging. People who took sotagliflozin had a 38% lower risk of major kidney problems. This included issues like a sharp drop in kidney function, needing dialysis, or even requiring a kidney transplant.
The drug also reduced the risk of serious heart and kidney-related problems by 23%. This included death due to kidney or heart conditions.
These numbers show how powerful sotagliflozin could be for people living with these serious health conditions. It offers a new way to manage both diabetes and kidney disease at the same time.
Sotagliflozin has already been approved by the U.S. Food and Drug Administration (FDA) under the name INPEFA. It’s approved to lower the risk of death from heart problems and to reduce hospital visits for heart failure. This makes it a helpful medication for people with heart disease or chronic kidney disease.
The research team believes that using a drug like sotagliflozin, which works on two targets instead of one, could be a big step forward in treating these health problems. It may help people live longer and healthier lives by preventing some of the worst outcomes of diabetes and kidney disease.
In summary, this new study gives hope to many people dealing with complex and serious health challenges. As more research continues, sotagliflozin could become a key part of treatment plans for patients all over the world.
Copyright © 2025 Knowridge Science Report. All rights reserved.
